Annual Total Long Term Liabilities
$12.97 M
+$12.97 M+100.00%
April 30, 2024
Summary
- As of February 8, 2025, PMCB annual total long term liabilities is $12.97 million, with the most recent change of +$12.97 million (+100.00%) on April 30, 2024.
- During the last 3 years, PMCB annual total long term liabilities has risen by +$12.97 million (+100.00%).
- PMCB annual total long term liabilities is now at all-time high.
Performance
PMCB Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$6.87 M
-$2.81 M-29.02%
October 31, 2024
Summary
- As of February 8, 2025, PMCB quarterly total long term liabilities is $6.87 million, with the most recent change of -$2.81 million (-29.02%) on October 31, 2024.
- Over the past year, PMCB quarterly long term liabilities has stayed the same.
- PMCB quarterly long term liabilities is now -63.61% below its all-time high of $18.88 million, reached on July 31, 2023.
Performance
PMCB Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
PMCB Long Term Liabilities Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +100.0% | 0.0% |
3 y3 years | +100.0% | +100.0% |
5 y5 years | +100.0% | +100.0% |
PMCB Long Term Liabilities Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | -100.0% | -63.6% | -100.0% |
5 y | 5-year | at high | -100.0% | -63.6% | -100.0% |
alltime | all time | at high | -100.0% | -63.6% | -100.0% |
PharmaCyte Biotech Long Term Liabilities History
Date | Annual | Quarterly |
---|---|---|
Oct 2024 | - | $6.87 M(-29.0%) |
Jul 2024 | - | $9.68 M(-25.4%) |
Apr 2024 | $12.97 M(>+9900.0%) | $12.97 M(-13.1%) |
Jan 2024 | - | $14.93 M(-4.1%) |
Oct 2023 | - | $15.57 M(-17.5%) |
Jul 2023 | - | $18.88 M(>+9900.0%) |
Apr 2023 | $0.00(0.0%) | $0.00(0.0%) |
Jan 2023 | - | $0.00(0.0%) |
Oct 2022 | - | $0.00(0.0%) |
Jul 2022 | - | $0.00(0.0%) |
Apr 2022 | $0.00(0.0%) | $0.00(0.0%) |
Jan 2022 | - | $0.00(0.0%) |
Oct 2021 | - | $0.00(0.0%) |
Jul 2021 | - | $0.00(0.0%) |
Apr 2021 | $0.00(-100.0%) | $0.00(-100.0%) |
Jan 2021 | - | $8400.00(-60.2%) |
Oct 2020 | - | $21.10 K(-37.4%) |
Jul 2020 | - | $33.70 K(-27.2%) |
Apr 2020 | $46.30 K(>+9900.0%) | $46.30 K(>+9900.0%) |
Jan 2020 | - | $0.00(0.0%) |
Oct 2019 | - | $0.00(0.0%) |
Jul 2019 | - | $0.00(0.0%) |
Apr 2019 | $0.00(0.0%) | $0.00(0.0%) |
Jan 2019 | - | $0.00(0.0%) |
Oct 2018 | - | $0.00(0.0%) |
Jul 2018 | - | $0.00(0.0%) |
Apr 2018 | $0.00(0.0%) | $0.00(0.0%) |
Jan 2018 | - | $0.00(0.0%) |
Oct 2017 | - | $0.00(0.0%) |
Jul 2017 | - | $0.00(0.0%) |
Apr 2017 | $0.00(0.0%) | $0.00(0.0%) |
Jan 2017 | - | $0.00(0.0%) |
Oct 2016 | - | $0.00(0.0%) |
Jul 2016 | - | $0.00(0.0%) |
Apr 2016 | $0.00(0.0%) | $0.00(0.0%) |
Jan 2016 | - | $0.00(0.0%) |
Oct 2015 | - | $0.00(0.0%) |
Jul 2015 | - | $0.00(0.0%) |
Date | Annual | Quarterly |
---|---|---|
Apr 2015 | $0.00(0.0%) | $0.00(0.0%) |
Jan 2015 | - | $0.00(0.0%) |
Oct 2014 | - | $0.00(0.0%) |
Jul 2014 | - | $0.00(0.0%) |
Apr 2014 | $0.00(0.0%) | $0.00(0.0%) |
Jan 2014 | - | $0.00(0.0%) |
Oct 2013 | - | $0.00(0.0%) |
Jul 2013 | - | $0.00(0.0%) |
Apr 2013 | $0.00(0.0%) | $0.00(-100.0%) |
Jan 2013 | - | $292.00 K(-66.5%) |
Oct 2012 | - | $872.00 K(+50.3%) |
Jul 2012 | - | $580.00 K(>+9900.0%) |
Apr 2012 | $0.00(-100.0%) | $0.00(-100.0%) |
Jan 2012 | - | $827.90 K(+42.7%) |
Oct 2011 | - | $580.00 K(0.0%) |
Jul 2011 | - | $580.00 K(0.0%) |
Apr 2011 | $580.00 K(-3.3%) | $580.00 K(>+9900.0%) |
Jan 2011 | - | $0.00(0.0%) |
Oct 2010 | - | $0.00(0.0%) |
Jul 2010 | - | $0.00(-100.0%) |
Apr 2010 | $600.00 K(-69.8%) | $600.00 K(+23.6%) |
Jan 2010 | - | $485.40 K(-73.3%) |
Oct 2009 | - | $1.82 M(-0.8%) |
Jul 2009 | - | $1.83 M(-7.6%) |
Apr 2009 | $1.99 M(+221.5%) | $1.99 M(>+9900.0%) |
Jan 2009 | - | $0.00(-100.0%) |
Jan 2007 | - | $591.40 K(-0.3%) |
Oct 2006 | - | $593.40 K(-0.4%) |
Jul 2006 | - | $595.50 K(-3.6%) |
Apr 2006 | $617.70 K(-53.7%) | $617.70 K(-51.5%) |
Jan 2006 | - | $1.27 M(-14.0%) |
Oct 2005 | - | $1.48 M(-0.9%) |
Jul 2005 | - | $1.50 M(+12.1%) |
Apr 2005 | $1.33 M(+305.6%) | $1.33 M(-55.7%) |
Jan 2005 | - | $3.01 M(-0.7%) |
Oct 2004 | - | $3.03 M(+1.4%) |
Jul 2004 | - | $2.99 M(+808.4%) |
Apr 2004 | $328.90 K | $328.90 K(+265.4%) |
Jan 2004 | - | $90.00 K |
FAQ
- What is PharmaCyte Biotech annual total long term liabilities?
- What is the all time high annual total long term liabilities for PharmaCyte Biotech?
- What is PharmaCyte Biotech annual total long term liabilities year-on-year change?
- What is PharmaCyte Biotech quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for PharmaCyte Biotech?
- What is PharmaCyte Biotech quarterly long term liabilities year-on-year change?
What is PharmaCyte Biotech annual total long term liabilities?
The current annual total long term liabilities of PMCB is $12.97 M
What is the all time high annual total long term liabilities for PharmaCyte Biotech?
PharmaCyte Biotech all-time high annual total long term liabilities is $12.97 M
What is PharmaCyte Biotech annual total long term liabilities year-on-year change?
Over the past year, PMCB annual total long term liabilities has changed by +$12.97 M (+100.00%)
What is PharmaCyte Biotech quarterly total long term liabilities?
The current quarterly long term liabilities of PMCB is $6.87 M
What is the all time high quarterly long term liabilities for PharmaCyte Biotech?
PharmaCyte Biotech all-time high quarterly total long term liabilities is $18.88 M
What is PharmaCyte Biotech quarterly long term liabilities year-on-year change?
Over the past year, PMCB quarterly total long term liabilities has changed by $0.00 (0.00%)